Groundbreaking Discoveries in Inflammation and Infection

BioAegis Therapeutics is a clinical stage company, developing novel protein replacement therapies targeted at saving lives. The portfolio is based on the endogenous human protein, plasma gelsolin (pGSN). Plasma gelsolin, recently discovered to be a key component of innate immunity, provides an immunotherapeutic approach to fighting pathogens. Additionally, the protein protects end organs against the effects of an uncontrolled and cascading inflammatory response in numerous diseases.

BioAegis’ unique set of assets includes a proprietary diagnostic, and a biomarker-driven clinical program in multiple high value indications. The pristine safety profile is supported by extensive animal research and Phase 1b/2a human clinical trials.